Tranexamic Acid for Melasma: Topical Evidence, Oral Trials and Safety Limits

Tranexamic Acid for Melasma: The Protocol Dermatologists Are Switching To

Last Updated: October 25, 2026

A melasma trial can report a 49% improvement with tranexamic acid and still tell you very little about the serum on your bathroom shelf. The missing detail is the route: that result came from oral treatment, not a cosmetic applied to the skin.

Medical disclaimer: Melasma is a medical pigmentation condition. This article explains research, not an individualized treatment or dosing plan. Consult a qualified clinician about diagnosis, prescriptions, pregnancy or breastfeeding, and treatment risks. Do not start oral tranexamic acid, alter hormonal medication or replace prescribed treatment based on this guide.

For the broader research context and related ingredient comparisons, start with our hyperpigmentation guide to dark spots, ingredients and evidence limits.

The decision that comes before a TXA protocol

“TXA for melasma” can mean oral medication, a topical preparation, an injected intervention or a procedure-assisted approach. Those are different interventions. A percentage on a cosmetic bottle cannot translate an oral trial into a serum benefit.

Clinical evidence synthesis: Feng et al. (2021), Journal of Clinical Pharmacy and Therapeutics, reviewed 24 trials involving oral, topical or intradermal TXA. Although several analyses favored TXA and scores improved from baseline, superiority was not detected when the topical or intradermal route was considered. Route-specific comparisons matter more than a broad headline that “TXA works.” PMID: 33959984.

Our tiers refer to a specific claim: Tier 1 means multiple randomized human trials; Tier 2 means limited human clinical evidence; Tier 3 means mainly laboratory or mechanistic evidence; Tier 4 means a clinical claim remains unconfirmed by the evidence reviewed. A favorable result does not automatically validate every preparation, route or use schedule.

What the topical placebo comparison actually found

Tier 2, with a negative between-treatment result: Kanechorn Na Ayuthaya et al. (2012), Journal of Cosmetic and Laser Therapy, enrolled 23 women in a 12-week split-face trial of 5% topical TXA against its vehicle, with sunscreen used alongside treatment. Twenty-one completed the trial. Both sides improved, but TXA did not produce significantly better lightening than the vehicle, and erythema was greater on the TXA side. PMID: 22506692.

The result does not prove every topical-TXA formula is ineffective. It does show why improvement from the first photograph is not sufficient evidence of an ingredient-specific effect. It also contradicts a blanket assurance that topical TXA never irritates. Kanechorn Na Ayuthaya et al. (2012), Journal of Cosmetic and Laser Therapy, PMID: 22506692.

Tier 4 for a universal serum protocol: This trial does not establish that 2–5% is an effective range for every formulation, that twice-daily application maximizes results or that everybody should expect meaningful fading within 8–12 weeks. A study's schedule is not a validated optimum for every cosmetic. Kanechorn Na Ayuthaya et al. (2012), Journal of Cosmetic and Laser Therapy, PMID: 22506692; Feng et al. (2021), Journal of Clinical Pharmacy and Therapeutics, PMID: 33959984.

The oral trial: benefit, then partial loss after stopping

Tier 2 for this individual randomized trial: Del Rosario et al. (2018), Journal of the American Academy of Dermatology, enrolled 44 people with moderate-to-severe melasma, with 39 completing the study. Oral TXA or placebo was used for three months alongside sunscreen, followed by three months with sunscreen alone. Modified Melasma Area and Severity Index scores fell 49% with TXA versus 18% with placebo at the end of treatment. This is a change in a severity score, not the proportion of people cured. PMID: 28987494.

Three months after stopping treatment, the reductions from baseline were 26% and 19%, respectively. The larger TXA benefit was not fully maintained. The study was single-center and enrolled predominantly Hispanic women; no serious adverse events were observed, but this small sample cannot exclude uncommon harms. Del Rosario et al. (2018), Journal of the American Academy of Dermatology, PMID: 28987494.

Tier 1 for broader randomized oral-treatment support, not universal safety: Feng et al. (2021), Journal of Clinical Pharmacy and Therapeutics, found the more favorable route-specific signal with oral TXA in their randomized-trial synthesis. The evidence supports a clinician-supervised treatment option, not self-prescribing or converting an oral result into a topical-product endorsement. PMID: 33959984.

Safety belongs to the route and the person

Safety review, not a zero-risk claim: Sheu (2018), Cutis, describes TXA's inhibition of the plasminogen-activation pathway and notes that thromboembolism risk can limit systemic use. The review also distinguishes the limited topical literature from systemic evidence. A mechanism can explain why a treatment is investigated without establishing that it is suitable for you. PMID: 29554171.

Oral treatment requires a clinician to assess medical history, medications and contraindications. A small trial reporting no serious events does not remove that need. Conversely, the oral risk profile should not be copied wholesale onto a cosmetic without route-specific evidence. Neither “same risk at every route” nor “no possible risk when topical” is established by the sources reviewed. Sheu (2018), Cutis, PMID: 29554171; Del Rosario et al. (2018), Journal of the American Academy of Dermatology, PMID: 28987494.

Are dermatologists universally replacing hydroquinone?

Expert consensus, not a replacement trial: Sarkar et al. (published online 2025), Journal of the European Academy of Dermatology and Venereology, developed an international Delphi consensus with 38 dermatologists from 11 countries. Its summary retained supervised hydroquinone-based triple-combination creams as the gold standard and identified options including topical azelaic acid, kojic acid and oral TXA. That is not support for the earlier headline's claim that dermatologists are switching everyone to a topical TXA protocol. PMID: 40996222.

Consensus integrates evidence and clinical judgment; it is not itself a randomized comparison. Choice and maintenance should be individualized rather than reduced to an ingredient trend.

Photoprotection is a treatment component, not an afterthought

Tier 2 for this specific sunscreen comparison: Castanedo-Cazares et al. (2014), Photodermatology, Photoimmunology & Photomedicine, randomized 68 people to UV-plus-visible-light sunscreen containing iron oxide or UV-only sunscreen for eight weeks; 61 completed treatment. Both groups also received 4% hydroquinone. The UV-plus-visible-light group had greater improvements in pigmentation outcomes. PMID: 24313385.

This supports discussing visible-light protection alongside broad-spectrum UV protection in melasma care. It does not prove every tinted cosmetic performs equivalently or that sunscreen alone produced the combined-treatment result. The international consensus also emphasized photoprotection. Castanedo-Cazares et al. (2014), Photodermatology, Photoimmunology & Photomedicine, PMID: 24313385; Sarkar et al. (published online 2025), Journal of the European Academy of Dermatology and Venereology, PMID: 40996222.

The evidence reviewed here does not quantify a universal “one missed day erases weeks” penalty. That alarmist rule is not necessary to explain why consistent protection matters.

A practical care discussion instead of an automatic serum stack

  1. Confirm the diagnosis. Ask whether the pigmentation is melasma, post-inflammatory pigmentation or another condition. Do not treat a changing or unexplained patch solely with cosmetic experimentation.
  2. Name the route. Ask whether a recommendation is for a topical cosmetic or oral medical treatment, and which study supports that specific intervention.
  3. Make photoprotection explicit. Discuss a suitable broad-spectrum sunscreen and the role of visible-light protection. Do not infer sunscreen performance from an unrelated cosmetic's color or ingredient list.
  4. Choose optional skincare for a defined purpose. If considering a topical serum, review the complete formula, label and prior reactions. Do not assume higher concentration or additional actives produce better results.
  5. Agree on reassessment and maintenance. Ask how progress will be evaluated, what to do if irritation occurs and how a response will be maintained. Do not interpret recurrence as a reason to escalate products on your own.

Where the catalog serum fits, and where it does not

ANUA Niacinamide 10% + TXA 4% Dark Spot Correcting Serum is an optional multi-active cosmetic in the catalog, which also lists arbutin. It is not the 5% TXA preparation in the vehicle-controlled trial and is not oral TXA. The catalog record establishes its listed identity and ingredients, not clinical equivalence or a treatment guarantee.

Tier 4 for the claimed synergy: The studies discussed here do not establish that this finished serum outperforms its individual ingredients or that adding separate niacinamide, arbutin, azelaic acid and vitamin C products improves its results. Different mechanisms are not a substitute for a comparison testing the proposed combination. Kanechorn Na Ayuthaya et al. (2012), Journal of Cosmetic and Laser Therapy, PMID: 22506692; Feng et al. (2021), Journal of Clinical Pharmacy and Therapeutics, PMID: 33959984.

For context, read our six-ingredient brightening evidence guide, the alpha arbutin versus kojic acid combination-trial analysis and why liquiritin trials do not validate every licorice extract.

Commercial disclosure: Veracil sells the serum below. It is an optional shopping example, not a prescribed melasma treatment or a product independently shown here to reproduce the cited trial results. Buying it is not required to follow the evidence discussion.

Shop This
ANUA Niacinamide 10% + TXA 4% Serum
Multi-active topical cosmetic listed with niacinamide, TXA and arbutin. Not equivalent to oral therapy or the trial's 5% TXA preparation; no established product-specific synergy or guaranteed melasma outcome here.
Shop Now

Honest limitations

TXA does not have one efficacy or safety profile independent of route. Oral evidence cannot validate a cosmetic, and a small negative topical study cannot settle every possible formulation. Severity-score improvements are not cures, rare harms cannot be excluded by small samples, and response can diminish after treatment stops. Del Rosario et al. (2018), Journal of the American Academy of Dermatology, PMID: 28987494; Kanechorn Na Ayuthaya et al. (2012), Journal of Cosmetic and Laser Therapy, PMID: 22506692; Sheu (2018), Cutis, PMID: 29554171.

The calibrated verdict

Confirmed, narrowly: Randomized oral-treatment evidence supports TXA as an option for appropriately selected patients under clinical supervision. It does not establish universal safety, permanent results or topical-serum equivalence. Feng et al. (2021), Journal of Clinical Pharmacy and Therapeutics, PMID: 33959984.

Inconclusive: The universal topical protocol and blanket claim that cosmetic TXA is replacing standard melasma care. The vehicle-controlled study did not demonstrate superior lightening, while the international consensus retained supervised triple-combination therapy as the gold standard. Kanechorn Na Ayuthaya et al. (2012), Journal of Cosmetic and Laser Therapy, PMID: 22506692; Sarkar et al. (published online 2025), Journal of the European Academy of Dermatology and Venereology, PMID: 40996222.

The useful protocol starts with diagnosis, route-specific evidence and follow-up, not a shopping list.

The Veracil Research Team

0 comments

Leave a comment